Ascentage Pharma Group International (NASDAQ:AAPG) Shares Up 6.8% – Should You Buy?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s stock price was up 6.8% on Wednesday. The company traded as high as $16.50 and last traded at $16.3910. Approximately 12,451 shares were traded during trading, an increase of 84% from the average daily volume of 6,777 shares. The stock had previously closed at $15.35.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on AAPG. BTIG Research reiterated a “buy” rating and issued a $48.00 price target on shares of Ascentage Pharma Group International in a report on Friday, August 21st. B. Riley Financial started coverage on Ascentage Pharma Group International in a research note on Wednesday, June 10th. They issued a “buy” rating and a $45.00 price target for the company. Finally, Raymond James Financial reissued a “buy” rating on shares of Ascentage Pharma Group International in a research report on Wednesday, June 10th. Two research analysts have rated the stock with a Strong Buy rating and eight have issued a Buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $46.43.

Ascentage Pharma Group International Price Performance

The company has a current ratio of 1.22, a quick ratio of 1.18 and a debt-to-equity ratio of 1.09. The stock’s 50-day simple moving average is $17.09 and its 200 day simple moving average is $19.64.

Ascentage Pharma Group International (NASDAQ:AAPG) last announced its earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The firm had revenue of $22.24 million for the quarter. As a group, sell-side analysts anticipate that Ascentage Pharma Group International – Unsponsored ADR will post -2.42 earnings per share for the current fiscal year.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical-stage biopharmaceutical company focused on discovering and developing therapies that target mechanisms involved in programmed cell death. The company’s research is primarily directed toward cancer and other serious diseases in which regulating apoptosis may offer therapeutic benefits.

Its pipeline includes small-molecule drug candidates designed to inhibit proteins that help cancer cells survive. Key programs have included lisaftoclax (APG-2575), a BCL-2 inhibitor being investigated for hematologic malignancies, and APG-115, an MDM2-p53 inhibitor under evaluation in oncology indications.